Even though the pharmacological inhibition of mTOR in EAC patients has led to limited clinical benefit so far [146], evidence exists regarding the potential anti-tumor effect of targeting the PI3K-AKT-mTOR pathway in ESCC preclinical models, through direct inhibition or via the suppression of upstream targets. The gene discussed is MTOR; the disease is neoplasm.